Vandetanib therapy in medullary thyroid cancer

Drugs of Today

Volumn 48, Issue 11, 2012, Pages 723-733

  Grabowski, Patricia ^a,b   Briest, F ^b,c   Baum, R P ^a   Zaknun, J J ^a   Kulkarni, H R ^a   Zeitz, M ^b   Horsch D ^a  

^a ZENTRALKLINIK BAD BERKA   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

EGFR; Medullary thyroid cancer; Proto oncogene c Ret; Vandetanib; VEGFR

Indexed keywords

AMISULPRIDE; ARSENIC; AXITINIB; BENFLUMETOL; BORTEZOMIB; CABOZANTINIB; CARBAMAZEPINE; CHLORPROMAZINE; CISAPRIDE; DABIGATRAN; DIGOXIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERYTHROMYCIN; HALOFANTRINE; HALOPERIDOL; METFORMIN; METHADONE; MIZOLASTINE; MOXIFLOXACIN; ONDANSETRON; PENTAMIDINE; PHENOBARBITAL; RIFAMPICIN; SUNITINIB; TOREMIFENE; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; ZUCLOPENTHIXOL;

ACUTE HEART FAILURE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANGIOGENESIS; APOPTOSIS; ARTICLE; ASPIRATION PNEUMONIA; AUTOPHOSPHORYLATION; CANCER CELL; CELL DIFFERENTIATION; CELL GROWTH; CELL MEMBRANE PERMEABILITY; CELL MIGRATION; CELL PROLIFERATION; DIARRHEA; DISEASE COURSE; DRUG APPROVAL; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EUROPE; FATIGUE; GENE; GENE FUNCTION; GENE MUTATION; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; IC 50; IN VITRO STUDY; LIVER METASTASIS; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MEDULLARY THYROID CANCER; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PROTO ONCOGENE; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REARRANGED DURING TRANSFECTION GENE; RESPIRATORY ARREST; RESPIRATORY FAILURE; SIDE EFFECT; SINGLE DRUG DOSE; STAPHYLOCOCCAL BACTEREMIA; THYROID CANCER; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG INTERACTIONS; HUMANS; PIPERIDINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-RET; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; THYROID NEOPLASMS;

EID: 84870178012     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2012.48.11.1867323     Document Type: Article

References (40)

1. Hazard, J.B., Hawk, W.A., Crile, G., Jr. Medullary (solid) carcinoma of the thyroid; a clinicopathologic entity. J Clin Endocrinol Metab 1959, 19(1): 152-61.
2. Kouvaraki, M.A., Shapiro, S.E., Perrier, N.D. et al. RET protooncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid 2005, 15(6): 531-44. (Pubitemid 40993726)
3. Baum, R.P., Kulkarni, H.R., Carreras, C. Peptides and receptors in image-guided therapy: theranostics for neuroendocrine neoplasms. Semin Nucl Med 2012, 42(3): 190-207.
4. Baum, R.P., Kulkarni, H.R. THERANOSTICS: From Molecular Imaging Using Ga-68 Labeled Tracers and PET/CT to Personalized Radionuclide Therapy - The Bad Berka Experience. Theranostics 2012, 2(5): 437-47.
5. Iten, F., Muller, B., Schindler, C. et al. Response to [90Yttrium-DOTA]-TOC treatment is associated with longterm survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial. Clin Cancer Res 2007, 13(22 Pt 1): 6696-702. (Pubitemid 350206806)
6. Kloos, R.T. Protecting thyroid cancer patients from untoward effects of radioactive iodine treatment. Thyroid 2009, 19(9): 925-8.
7. Roman, S., Lin, R., Sosa, J.A. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 2006, 107(9): 2134-42. (Pubitemid 44665646)
8. Phay, J.E., Shah, M.H. Targeting RET receptor tyrosine kinase activation in cancer. Clin Cancer Res 2010, 16(24): 5936-41.
9. Hofstra, R.M., Landsvater, R.M., Ceccherini, I. et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 1994, 367(6461): 375-6.
10. Eng, C., Mulligan, L.M., Healey, C.S. et al. Heterogeneous mutation of the RET proto-oncogene in subpopulations of medullary thyroid carcinoma. Cancer Res 1996, 56(9): 2167-70. (Pubitemid 26119920)
11. Elisei, R., Ugolini, C., Viola, D. et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab 2008, 93(10): 3943-9.
12. Moura, M.M., Cavaco, B.M., Pinto, A.E. et al. Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas. Br J Cancer 2009, 100(11): 1777-83.
13. Santoro, M., Carlomagno, F., Romano, A. et al. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 1995, 267(5196): 381-3.
14. Capp, C., Wajner, S.M., Siqueira, D.R., Brasil, B.A., Meurer, L., Maia, A.L. Increased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2, in medullary thyroid carcinoma. Thyroid 2010, 20(8): 863-71.
15. Rodriguez-Antona, C., Pallares, J., Montero-Conde, C. et al. Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis. Endocr Relat Cancer 2010, 17(1): 7-16.
16. Sherman, S.I. Targeted therapies for thyroid tumors. Mod Pathol 2011, 24(Suppl. 2): S44-S52.
17. Carlomagno, F., Vitagliano, D., Guida, T. et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002, 62(24): 7284-90. (Pubitemid 36025251)
18. Carlomagno, F., Guida, T., Anaganti, S. et al. Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene 2004, 23(36): 6056-63. (Pubitemid 39178858)
19. Vitagliano, D., De, F.V., Tamburrino, A. et al. The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells. Endocr Relat Cancer 2011, 18(1): 1-11.
20. Carlomagno, F., Guida, T., Anaganti, S. et al. Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474. Endocr Relat Cancer 2009, 16(1): 233-41.
21. Johanson, V., Ahlman, H., Bernhardt, P. et al. A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinase-driven tumorigenesis. Endocr Relat Cancer 2007, 14(2): 433-44. (Pubitemid 47242641)
22. Broutin, S., Dupuy, C., Caillou, B., Lazar, V., Ryan, A., Schlumberger, M., Bidart, J.-M. In vitro and in vivo activity of vandetanib in a human medullary thyroid carcinoma model bearing a RETC634W activating mutation. Proc Am Assoc Cancer Res [100th Annu Meet Am Assoc Cancer Res (AACR) (April 18-22, Denver) 2009] 2009, 50: Abst 1788.
23. Walter, M.A., Benz, M.R., Hildebrandt, I.J. et al. Metabolic imaging allows early prediction of response to vandetanib. J Nucl Med 2011, 52(2): 231-40.
24. Verbeek, H.H., Alves, M.M., de Groot, J.W., Osinga, J., Plukker, J.T., Links, T.P., Hofstra, R.M. The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells. J Clin Endocrinol Metab 2011, 96(6): E991-E5.
25. Wedge, S.R., Ogilvie, D.J., Dukes, M. et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002, 62(16): 4645-55.
26. Knowles, P.P., Murray-Rust, J., Kjaer, S. et al. Structure and chemical inhibition of the RET tyrosine kinase domain. J Biol Chem 2006, 281(44): 33577-87. (Pubitemid 46036738)
27. Martin, P., Oliver, S., Kennedy, S.J., Partridge, E., Hutchison, M., Clarke, D., Giles, P. Pharmacokinetics of vandetanib: three phase I studies in healthy subjects. Clin Ther 2012, 34(1): 221-37.
28. Holden, S.N., Eckhardt, S.G., Basser, R. et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 2005, 16(8): 1391-7. (Pubitemid 41158486)
29. Tamura, T., Minami, H., Yamada, Y. et al. A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. J Thorac Oncol 2006, 1(9): 1002-9. (Pubitemid 47181370)
30. Zhang, L., Li, S., Zhang, Y. et al. Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study. Clin Ther 2011, 33(3): 315-27.
31. Wells, S.A., Jr., Gosnell, J.E., Gagel, R.F. et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010, 28(5): 767-72.
32. Robinson, B.G., Paz-Ares, L., Krebs, A., Vasselli, J., Haddad, R. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2010, 95(6): 2664-71.
33. Wells, S.A., Jr., Robinson, B.G., Gagel, R.F. et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012, 30(2): 134-41.
34. Vandetanib to treat children and adolescents with medullary thyroid cancer (NCT00514046). ClinicalTrials.gov Web site, Accessed October 22, 2012.
35. Study to determine if contacting patients with MTC more frequently results in earlier detection and treatment of signs and symptoms of AEs and thus a decrease in the percentage of time patients experience AEs during first 12 months on vandetanib treatment (88) (NCT01298323). ClinicalTrials.gov Web site, Accessed October 22, 2012.
36. A targeted phase I/II trial of ZD6474 (vandetanib; ZACTIMA) plus the proteasome inhibitor, bortezomib (Velcade(R)), in adults with solid tumors with a focus on hereditary or sporadic, locally advanced or metastatic medullary thyroid cancer (NCT00923247). ClinicalTrials.gov Web site, Accessed October 22, 2012.
37. To compare the effects of two doses of vandetanib in patients with advanced medullary thyroid cancer (NCT01496313). ClinicalTrials.gov Web site, Accessed October 22, 2012.
38. Duplomb, S., Benoit, A., Mechtouff-Cimarelli, L., Cho, T.H., Derbel, O., Peix, J.L., de la Fouchardiere, C. Unusual adverse event with vandetanib in metastatic medullary thyroid cancer. J Clin Oncol 2012, 30(2): e21-e3.
39. Chatal, J.F., Kraeber-Bodere, F., Goldenberg, D.M., Barbet, J. Treatment of metastatic medullary thyroid cancer with vandetanib: need to stratify patients on basis of calcitonin doubling time. J Clin Oncol 2012, 30(17): 2165.
40. German Institute for Quality and Economics in the Health Care System (IQWiG). https://www.iqwig.de/sidaov4vdaulq9389rndo0gn20ur3064nh5/download/A12- 09-Vandetanib-Kurzfassung-Nutzenbewertung-35a-SGB-V.pdf. Accessed October 22, 2012.C